Daiichi Sankyo partners with Ultragenyx for gene therapy manufacturing technology

1 April 2020
daiichi-charles-big

Japan’s Daiichi Sankyo (TYO: 4568) has entered into a strategic partnership for the non-exclusive use of Ultragenyx Pharmaceutical’s (Nasdaq: RARE) proprietary adeno associated virus (AAV) based gene therapy manufacturing technology.

Daiichi Sankyo is currently doing discovery research for gene therapy drugs using AAV vectors, and in order to deliver gene therapy drugs to patients in the future, it is essential to also establish in-house manufacturing technology at an early stage. Ultragenyx has developed its own AAV production system using HeLa and HEK293 cells, which is particularly excellent in terms of stable quality, high production efficiency, and mass production capability.

Financial terms of the accord

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology